Acute tubulointerstitial nephritis and renal amyloidosis: A rare complication of Atezolizumab

First author: Naqib Ullah

Journal: Cureus

Reference : DOI : 10.7759/cureus.49533

Link to article: https://pubmed.ncbi.nlm.nih.gov/38156149/

Introduction:

Lung cancer is the second most common malignancy. The two types of lung cancer are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Among current treatments, anti-PD-1 or anti-PD-L1 agents (checkpoint inhibitors (PKIs): pembrolizumab and atezolizumab) represent adjuvant therapy in lung cancer. The most frequently reported adverse events with ICPs are diarrhea, pneumopathy and drug-induced hepatitis.

The authors report here the case of a 70-year-old man who received Atezolizumab as adjuvant therapy and developed nephrotic-like proteinuria, revealing AA amyloidosis and atezolizumab-induced interstitial nephritis.

Résumé Article Néphrite tubulointerstitielle aiguë et amylose rénale

.pdf

Download PDF • 756KB